About Me

I’m a clinical pharmacist with nearly four decades of experience across hospital practice, sterile compounding, national formulary policy, and federal regulatory analysis. My work has spanned the full lifecycle of pharmaceuticals, from bedside therapeutics to post-market evaluation. I now apply that experience to critically examining mRNA vaccine science, LNP pharmacology, and regulatory oversight.

Hospital & Clinical Foundations (20 years)

I spent two decades in hospital pharmacy as a clinician-educator, antimicrobial stewardship specialist, and Clinical Pharmacy Manager. My stewardship program received national recognition, and my practice included direct patient care, therapeutic decision-making, and interdisciplinary education.

Quality, Safety & Compounding Systems

As a consultant, I helped implement a new sterile compounding clean room for chemotherapy and bulk compounding which integrating engineering controls, workflow design, quality assurance, and contemporary sterile standards. This gave me first-hand experience in the manufacturing, safety, and regulatory principles that are now central to understanding mRNA vaccine production.

Formulary & Policy Expertise (5 years)

I worked at the national level conducting drug utilization reviews, formulary evaluations, and therapeutic class analyses. This required integrating clinical evidence, real-world data, pharmacoeconomics, and system-wide impact — skills that directly inform my current analysis of modRNA/LNP technologies.

Federal Regulatory & Post-Market Analysis (10 years, PMPRB)

For a decade, I worked at Canada’s Patented Medicine Prices Review Board (PMPRB), focusing on post-market pharmaceutical assessment, evidence interpretation, therapeutic class reviews, and national pricing and policy frameworks. This experience gave me insight into how regulatory decisions are made, how sponsor-submitted data is evaluated, and where oversight can fail.

Clinical Authorship & National Contributions

I authored two chapters in CPhA’s Therapeutic Choices considered a core clinical reference for Canadian physicians and pharmacists. I have expertise in translating evidence into clear, practice-ready guidance.

Why I Write

Because the public conversation has been dominated by viewpoints outside pharmaceutics and drug safety…. and because meaningful oversight must include the perspectives of those who understand how drugs are formulated, manufactured, behave in the body, and are evaluated post-market.

I write to bring that missing expertise into the discussion.

Why subscribe?

Subscribe to get full access to the newsletter and website. Never miss an update.

Stay up-to-date

You won’t have to worry about missing anything. Every new edition of the newsletter goes directly to your inbox.

Join the crew

Be part of a community of people who share your interests.

To find out more about the company that provides the tech for this newsletter, visit Substack.com.